Company Encyclopedia
View More
name
Instil Bio
TIL.US
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. Its lead products candidate is AXN-2510/IMM2510 that is in Phase 1b/2 clinical trial for the treatment of patients with chemotherapy in patients with advanced/metastatic non-small cell lung cancer. The company also conducts a Phase 1 open label trial in China for AXN-2510/IMM2510 as monotherapy in patients with advanced solid tumors, including triple-negative breast cancer, squamous non-small cell lung cancer, hepatocellular carcinoma, renal cell carcinoma, and rare solid tumors, such as soft tissue sarcomas and thymic cancer. Instil Bio, Inc.
1.875 T
TIL.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Instil Bio | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    TIL
    +11.19%
    LB filings·
    US
    TIL
    +11.19%

    Instil Bio Q3 net loss per share narrows

    Instil Bio's Q3 net loss per share improved to $2.01 from $3.54 year-over-year. The company's cash and investments decreased to $83.4 million from $115.1 million. Research and development expenses rose to $9.1 million from $0.6 million, indicating investment in clinical trials. Analysts rate the stock as a "buy," with a median 12-month price target of $88.00, significantly above the current price of $14.99.

    Reuters·
    US
    TIL
    +11.19%
    Reuters·
    US
    TIL
    +11.19%

    Instil Bio | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    TIL
    +11.19%
    LB filings·
    US
    TIL
    +11.19%

    Instil Bio Inc expected to post a loss of $2.35 a share - Earnings Preview

    Instil Bio Inc is expected to report a loss of $2.35 per share for the quarter ending September 30, 2025, with no change in quarterly revenue. The average analyst rating is "buy," with a median 12-month price target of $88.00, significantly above its last closing price of $15.02. Previous earnings reports show mixed results, with several misses and a few beats in the last quarters. The mean earnings estimate has remained unchanged over the last three months.

    Reuters·
    US
    TIL
    +11.19%
    Reuters·
    US
    TIL
    +11.19%

    Instil Bio CFO and CBO Sandeep Laumas Sells All Common Stock Holdings

    Reporter NameLaumas SandeepRelationshipCFO and CBOTypeSellAmount$701,667SEC FilingForm 4Sandeep Laumas, serving as CFO and CBO of Instil Bio, sold a total of 30,000 shares of Common Stock on September 10, 2025, in two separate transactions. The first sale was at a weighted average price of $23.04 per share, and the second at $23.88 per share, totaling $701,667. Following these transactions, Laumas no longer directly owns any Common Stock in Instil Bio.SEC Filing: Instil Bio, Inc. [ TIL ] - Form 4 - Sep. 12, 2025

    TradingView·
    US
    TIL
    +11.19%
    TradingView·
    US
    TIL
    +11.19%